ejpmr, 2023,10(7), 557-568

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

IMPORTANCE OF CLINICAL TRIALS IN CANCER RESEARCH

Nahid*, Rachana Vemula and Mohammad Saiena

Pharm D, Student at Clino Sol Research.

***Corresponding Author: Nahid**

Pharm D, Student at Clino Sol Research.

Article Received on 22/05/2023 **Article Revised on 12/06/2023** **Article Accepted on 02/07/2023**

ABSTRACT

Clinical trials play a crucial role in advancing cancer research and improving patient outcomes. This abstract explores the importance of clinical trials in cancer research, highlighting their significant impact on the development of new therapies, understanding disease mechanisms, and enhancing patient care. Clinical trials provide a platform for evaluating the safety and efficacy of novel interventions, including targeted therapies, immunotherapies, and combination treatments. They enable researchers to investigate the effectiveness of these interventions in diverse patient populations and assess their potential side effects. By conducting rigorous clinical trials, the scientific community gains valuable insights into the optimal treatment strategies for different types and stages of cancer. Furthermore, clinical trials promote the integration of personalized medicine, enabling the identification of biomarkers and genetic profiles that can guide tailored treatment approaches. Through the participation of cancer patients in clinical trials, individuals gain access to cutting-edge therapies and specialized care, often leading to improved outcomes and extended survival rates. Additionally, clinical trials contribute to the expansion of scientific knowledge and the development of evidence-based guidelines for cancer management. They serve as a vital bridge between preclinical research and clinical practice, facilitating the translation of promising discoveries into practical, patient-centered interventions. However, challenges such as patient recruitment, regulatory processes, and ethical considerations exist and need to be addressed to ensure the successful implementation of clinical trials in cancer research. In conclusion, clinical trials are essential for advancing cancer research and improving patient care. Their significance lies in the evaluation of novel therapies, the identification of personalized treatment approaches, and the generation of evidence-based knowledge that drives progress in the fight against cancer.

KEYWORDS: Clinical trials, Cancer research, Novel therapies, Patient outcomes, Targeted therapies, Immunotherapies.

INTRODUCTION

Clinical trials help inform our understanding of cancer and improve prevention, diagnosis, treatment, and care they show us what works and what doesn't and help build the future of medicine.

They are the best way to answer critical questions about cancer, from preventing it in the first place, to finding and diagnosing it, treating it, and managing its symptoms and the side effects of its treatments.

Cancer prevention clinical trials represent the maturation of decades of epidemiologic and laboratory investigations, resulting in the identification of exogenous and endogenous factors that influence cancer risk. Cancer prevention strategies have included lifestyle and medical approaches; as associated cancer risk factors are identified in each milieu, clinical trials are conducted to investigate these associations.

Current cancer prevention approaches have been facilitated by advances in basic research in a wide variety of scientific fields; an increased understanding of genetic, nutritional, and other environmental influences on cancer; significant advances in bioinformatics and technology; and proven strategies in behavioral sciences that have accelerated the translation of research to the clinical setting. The National Cancer Institute (NCI)[3] has supported cancer prevention clinical trials for the past 25 y using a systematic, phased approach to investigate natural and synthetic agents.

Novel therapies in cancer treatment:

Novel therapies mean treatment procedures which are developed recently. Novel cancer therapies are focused on targeting only those cells which are cancerous and giving less damage to normal cells. Novel therapies like immunotherapy are targeted approaches to curing cancer killing only cancerous cells.

Types of novel therapies in cancer treatment



Types of clinical trials

Phase 1 trials

Phase I trials that accounts for the first step for volunteer testing. In this trial, a small number of volunteers (20-100) are selected for the study. Generally, this phase has been conducted in order to analyze the safety, tolerance, pharmacodynamics and pharmacokinetic properties of a drug.

These trials are often performed in clinical centres where the subjects are kept under observations by full–time staff. Also, the clinics of such clinical trials have been often run by the private contract research organizations (CRO) who perform these trials on the behalf of researcher or pharmaceutical companies. The Phase I trials consists of the normal ranging of dose and are also called as dose magnifying studies, so that the safest and best dose can be determined.

Phase 2 trials

In Phase II trials, the studies have been conducted in vast groups (100- 300) and are designed to analyze working of drug along with Phase 1 assessment of safety in the larger participants.

The Phase II trials have been divided into two groups which include Phase IIa clinical trials that rare designed to analyze the dosing requirement, and Phase IIb trials which have been designed to analyze the drug efficacy.

Phase 3 trials

Phase III clinical trials have been suggested to be designed in order to analyze the efficacy of new drug and its therapeutic effect in clinical practices.

Phase III trials have been conducted randomly on large number of patients (300-3000 or more), having the target to achieve the definite assessment of the new drug, by comparison with the standard drug treatment. Also, due to their longer duration and size, the Phase III trials have been considered as the most expensive, time consuming and difficult to design and run.

Phase 4 trials

Phase IV, also referred to as "Post marketing surveillance" (pharmacovigilance), includes the technical support of the drug after the selling permission of the drug is achieved. The Phase IV studies can be performed with the help of regulatory authority or by sponsoring company for finding a new market of the drug.

Such trails have been designed to find out if any long term adverse effect over a much large population of patients for a longer period of time, that were not possible during Phase II and phase III trials, has been noted. However, the whole process of the drug from the lab to this point takes about 12-18 years approximately.

Key consideration in clinical trials



1. **Informed consent-** Is an ongoing process that must occur before any clinical trial-related procedures are conducted. The process consists of documentation and a series of conversations between the clinical trial participant and the principal investigator and delegated health care professionals, as appropriate.

a) **Elements of informed consent** - An informed consent resides on its three critical and essential elements including voluntarism, information disclosure, and decision-making capacity.

b) **Informed consent Guidelines-**Investigators must follow the International Council on Harmonization (ICH) good clinical practice (GCP) guidelines Section 1.28 describes the informed consent process, while Section 4.8 explains the requirements and process for obtaining informed consent from a clinical trial participant.11 The informed consent document must be fully approved by an institutional review board (IRB) or an independent ethics committee (IEC) prior to its use with trial participants.

2. **Patient enrolment-** Recruiting the planned sample size within the defined time frame in clinical trials has proven to be the chief bottleneck in the drug development process. 3 The process of enrolling in clinical trials is carefully regulated in order to protect the participants and maintain the clinical trial's internal validity. Before a participant can enroll in a clinical trial, they must be recruited, screened, and give their informed consent.

Screening Process and Enrolling in clinical trials

Prior to formal enrolment in a clinical trial patients who are interested in participating will go through a screening process. Inclusion and exclusion criteria. and Patient's eligibility whether or not they can enter the clinical trial.

Once the screening process determines that the patient meets the inclusion criteria, the patient has a consultation where more information about the trial is provide and an Informed Consent Form is signed. The informed consent process is one of the things that contributes significantly to the protection of patients during their participation in a clinical trial.

Ethics in Clinical Research & Patient safety

Ethical strategies ensure the integrity of the research results; they also protect the safety of patients who volunteer to participate in the trials.

Codes of Ethics-Several formal documents and ethical frameworks provide moral guidance for clinical researchers 5 and this codes are Nuremberg Code (1947), Declaration of Helsinki (2000), Belmont Report (1979), CIOMS (2002), U.S. Common Rule (1991) clinical trials need to be conducted following established standards like International Conference on Harmonization Good Clinical Practice (ICH-GCP) Guidelines, International Ethical Guidelines for Biomedical Research Involving Human Subjects issued by the Council for International Organizations Medical Sciences (CIOMS), and the ethical principles outlined in the Declaration of Helsinki.

Randomization & Control group

The randomized control trial (RCT) is a trial in which subjects are randomly assigned to one of two groups: one (the experimental group) receiving the intervention that is being tested, and the other (the comparison group or control) receiving an alternative (conventional) treatment

The two groups are then followed up to see if there are any differences between them in outcome.

The results and subsequent analysis of the trial are used to assess the effectiveness of the intervention, which is the extent to which a treatment, procedure, or service does patients more good than harm. RCTs are the most stringent way of determining whether a cause-effect relation exists between the intervention and the outcome.

End point Measurement and Data analysis

Endpoints are measures which can be observed or calculated for each subject on a trial. Often these measures are combined together mathematically in various ways to estimate a statistic. All statistics have associated measures of uncertainty. The combination of

the statistic and the measure of uncertainty can be used to calculate confidence intervals and *p* values which we typically use to interpret clinical trials results 9 Data analysis methods are an integral part of modern clinical research.

Promising novel therapies in cancer treatment

Immunotherapy is a type of cancer treatment. It uses substances made by the body or in a laboratory to boost the immune system and help the body find and destroy cancer cells.

Types

Check point inhibitors

- Checkpoint inhibitors are a type of immunotherapy. They block proteins that stop the immune system from attacking the cancer cells. Our immune system protects us from disease, killing bacteria and viruses. One main type of immune cell that does this is called a T cell. cells have proteins on them that turn on an immune response and other proteins that turn it off. These are called checkpoint proteins. Some checkpoint proteins help tell T cells to become active, for example when an infection is present. 13

CAR T-cell therapies-

- The initial development of CAR T-cell therapies focused largely on the most common cancer in children, acute lymphoblastic leukemia (ALL).14 Since 2017

six CAR T-cell therapies have been approved by the

Food and Drug Administration (FDA). All are approved for the treatment of blood cancers, including lymphomas, some forms of leukemia, and, most recently, multiple myeloma.

FDA approved treatment Axicabtagene ciloleucel, Brexucabtagene autoleucel, Ciltacabtagene autoleucel , Idecabtagene vicleucel, Lisocabtagene maraleucel and Tisagenlecleucel 15

Cancer vaccines-

- All vaccines work by training your immune system to defend your body against foreign invaders or abnormal cells that pose a threat. There are two main types of cancer vaccines: Preventive Cancer Vaccines &Therapeutic Cancer Vaccines .There are currently four vaccines that are approved by the FDA that can help prevent cancer, in addition to two FDA-approved vaccines for the treatment of cancer:

Preventive Cancer Vaccines-Cervarix, Gardasil, Gardasil-9,Hepatitis B (HBV) vaccine

Therapeutic Cancer Vaccines-Bacillus Calmette-Guérin (BCG) & Sipuleucel-T

Targeted therapies

Targeted therapy is a type of cancer treatment. It uses drugs to target specific genes and proteins that help cancer cells survive and grow. Targeted therapy can treat many different types of cancer. It can also be used in combination with other cancer treatments, such as chemotherapy.

Tyrosine kinase inhibitors

- Tyrosine kinase inhibitors (TKI) are a group of pharmacologic agents that disrupt the signal transduction pathways of protein kinases by several modes of inhibition. Tyrosine kinase inhibitors (TKIs) are a type of targeted therapy. TKIs come as pills, taken orally. A targeted therapy identifies and attacks specific types of cancer cells while causing less damage to normal cells. The following four TKI drugs are approved as first-line treatment for chronic phase CML. Imatinib, mesylate, Dasatinib , Nilotinib & Bosutinib

Monoclonal antibodies

- Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing. They all have names that include 'mab' at the end of their generic name. For example, trastuzumab (Herceptin) and rituximab (Mabthera)

Proteasome inhibitors

- The proteasome is a multicatalytic enzyme complex responsible for the majority of protein degradation in cells. proteasome helps to remove signals that promote transcription, cell growth, angiogenesis, and cell adhesion. inhibit the proteasome's activity will promote cell cycle arrest and induce apoptosis in tumor cells, thus establishing the proteasome as a promising potential target for anticancer therapy

Gene therapy

Cancer gene-therapy is the transfer of nucleic acids into tumour or normal cells to eliminate or reduce tumour burden by direct cell-killing, immunomodulation, or correcting genetic errors to reverse the malignant state. Genes may also be incorporated into normal tissues to enhance resistance to conventional cancer treatments.[20]

This treatment technique is very flexible, and a wide range of genes and vectors are being used in clinical trials with successful outcomes.[2]

Types



Recent Clinical Trials and Their finding

Clinical trial of cervical cancer on immunotherapy

Cervical cancer is the most common gynecologic malignancy, with over 500 000 estimated cases annually worldwide, resulting in 311 000 deaths.[1] The burden is highest in developing countries with limited access to appropriate screening and treatment resources. The pathogenesis of cervical cancer is typically driven by infection with high-risk strains of human papillomavirus (HPV).[9] The role of the immune system in clearing HPV infection[10] and increased incidence of cervical cancer in patients with HIV[11] provide a strong rationale for the use of immunomodulatory therapies in cervical cancer. The recent success of immunotherapy across many cancer types, including in other HPV-driven malignancies,

Clinical trials: Definitive treatment - The Gynecologic Oncology Group conducted a phase I trial (GOG-9929) testing the sequential addition of the anti-CTLA-4 checkpoint inhibitor ipilimumab after standard definitive chemo radiation for patients with node-positive cervical cancer.[20] Ipilimumab was administered for four cycles every 21 days at two different dose levels: 3 mg/kg and 10 mg/kg. Twenty-one patients were enrolled and completed at least two cycles of ipilimumab. Only two dose-limiting toxicities were observed across the entire study Initial oncologic outcomes from the study were also promising, with a 1-year progression-free survival of 81% and overall survival of 90%.

Clinical trials: Metastatic disease- Immune checkpoint inhibitors targeting both the PD-L1 and CTLA-4 axes have also been studied in the setting of recurrent or metastatic cervical cancer Ipilimumab was delivered at 10 mg/kg every 3 weeks for four cycles, followed by four cycles of maintenance therapy every 12 weeks. Unfortunately, clinical responses were disappointing These data suggest that anti-CTLA-4 agents are probably ineffective as monotherapy for metastatic disease.

Beyond Checkpoint Blockade: Emerging Immunotherapeutic Approaches- Checkpoint inhibitors are the best studied class of immunotherapy for cervical cancer, but numerous other strategies to activate the immune system have been proposed. Novel immunotherapeutic approach uses a patient’s own tumor-reactive T cells. These are cultured from samples of a metastatic tumor or draining lymph node[38] and tested for activity against E6 and E7 proteins. Initial data from nine patients with metastatic disease showed three responses, including two complete responses. The cohort was expanded to 18 patients and longer-term follow-up data were recently published.[40] The two patients with a complete response remained free of disease at 53 and 67 months after treatment.

Radiation and Immunotherapy- Since radiation therapy is frequently used as a component of cervical cancer management, potential synergies between radiation treatment and immunotherapy are another exciting area of ongoing investigation. Pre-clinical data show an improved response to treatment with combination therapy including both anti-CTLA-4 and PD-1 agents as well as radiation.[45] The improved response with all three therapies suggests complementary mechanisms, with the CTLA-4 inhibition reducing immunosuppressive Treg cells, anti PD-1 therapy preventing immune exhaustion of CD8 positive cells, and radiation treatment enhancing the diversity of T-cell receptors present on tumor-infiltrating lymphocytes

Targeted therapy of hepatocellular carcinoma: Present and Future- The encouraging results of sorafenib in advanced hepatocellular carcinoma (HCC), targeted therapy has become a new direction of research in the treatment of HCC. pathogenesis and progression of HCC are mediated by a number of molecular defects and dysregulated pathways. Novel targeted therapies are designed to inhibit the aberrant pathways at a molecular level with an aim to improve the clinical outcome.

Targeted therapeutic options and future perspectives for HER2-positive breast cancer- Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) are commonly recommended anti-HER2 target agents by the U.S. Food and Drug Administration. Combinations of trastuzumab with other agents have been associated with a longer disease-free progression (median, 7.4 vs 4.6 months; $p < 0.001$), a longer survival duration (median survival time, 25.1 vs 20.3 months; $p < 0.01$), a lower 1-year mortality rate (22% vs 33%; $p < 0.008$), a higher rate of objective response (50% vs 32%; $p < 0.001$), and a longer response duration (median, 9.1 vs 6.1 months; $p < 0.001$) adverse events (AEs) have been linked to the use of trastuzumab, including acute cardiac toxicity in congestive heart failure (CHF), gastrointestinal symptoms, minor hematologic deficiencies, and pulmonary symptoms.

On 8 June 2012, the FDA approved the combination of pertuzumab with trastuzumab and docetaxel, as first-line treatment in HER2-positive MBC.CLEOPATRA study describes a 40% ORR rate with multiple complete and partial responses.

Afatinib, as an oral small molecule, irreversibly inhibits HER1, -2, and -4 receptors.125 A phase II study in trastuzumab-resistant metastatic patients showed partial response in patients with progressive HER2-positive breast cancer.126 The most frequent AEs related to Afatinib include diarrhea and rash.

Challenges and future directions

1. Patient Recruitment and Retention

Successful recruitment of patients is one of the most challenging factors in conducting clinical trials. Inadequate patient retention during the conduct of the trial affects the definitive results.

Among the most frequently encountered challenges in subject recruitment was the complexity of the study protocol. In addition, there was a lack of awareness about clinical trials in patients, and sociocultural problems related to trial participation.

Barriers to subject recruitment

- Lack of awareness about clinical trials in patients
- The complexity of the study protocol
- Social and cultural issues related to trial participation.
- Potential strategies to enhance subject recruitment
- Having a dedicated CRC for trial
- Arranging for patient transport to the trial site for study visits
- Designing a recruitment strategy before study initiation
- Interacting with the medical community in your area regarding clinical trial recruitment
- Educating subjects on clinical during routine outpatient department (OPD) visits
- Creating positive awareness about clinical trials among people through press and mass media.

Barriers to subject retention

- Lack of awareness regarding the side effects in clinical trials
- Change of residence of the trial subject
- Experiencing side effects
- Subject's fear of the study procedures
- Inadequate compliance to study protocol on the improvement of subjects in clinical trials

International literature has reported innovative strategies [Table 1] to improve patient recruitment and retention in clinical trials. It would be interesting to study and know the relevance of implementing these strategies to enhance retention in the Indian population.

Category	Recruitment strategies	Retention strategies
Patient contact	Patient information (appropriate design and translation) Promotion (newsletters, advertisements, presentations, events, press release, and community sessions)	Additional contacts (reminders, newsletters, feedback for patients, and websites)
Patient convenience		Flexible appointments Reducing research burden (shortened assessment scales and online data collection)
Support for recruiters	Presentations and training about recruitment issues to recruitment staff	Presentations and training about retention issues to recruiting staff
Monitoring and systems	Recruitment staff reminders (computer pop-ups) Use of existing registers (mail shots and screening notes) Reducing trial burden (providing phone number for queries, and simple case report forms)	Reminders (calendars, alert cards, regular contacts with control, and potential trial participants)
Incentives	Targets (site recruitment targets, feedback, and competition among sites)	Incentives (gifts for sites, co-authorship, financial incentives)
Design	Relevance of study design Pilot studies Changing protocol (widening criteria) Patient and public involvement	Options other than complete withdrawal Patient and public involvement
Resources	Site resources Additional resources (such as networks)	
Human factors	Building relationships (on-site initiation visits, regular contact with recruitment staff)	Building relationships with trial patients (support for patient between visits, sending festival/ birthday cards, and thanking participants)

2. Cost and Access to novel therapies

The escalating cost of novel therapies creates significant challenges for patients and healthcare systems correspondingly. Limited access to expensive treatments may lead to discrimination in healthcare outcomes. Addressing this challenge requires collaborative efforts from various stakeholders. Key strategies include fostering competition among pharmaceutical companies, promoting value-based pricing models, encouraging regulatory reforms, and supporting research into alternative therapeutic approaches.

Academies or charities that perform or fund basic and preclinical research generally do neither have the expertise nor the financial resources to conduct clinical trials that are necessary to obtain market authorization for novel drugs or therapy. During the past two decades, academic scientists have therefore established collaborations with small or large companies or founded biotechnology start-ups to make the process economically sustainable. Nevertheless, the investments needed to take an ATMP to marketing authorization are very high, not just due to the costs of running clinical trials but also the manufacturing costs of viral vectors and cellular products and the stringent standards imposed by regulatory agencies to ensure the safety and quality of these products. Moreover, the patient population who would benefit from these therapies is often very small, ranging from several thousand for less rare diseases few additional issues aside from the commercial viability of ATMPs for rare diseases need to be considered. First, whichever solution is proposed in the EU or the USA should be adopted internationally once differences in regulation and reimbursement procedures are settled, though these may take several years at best. Unfortunately, developing countries may remain excluded from accessing these therapies, unless patients travel to specialized centers in Europe or the USA to receive the therapy. This is a problem to be addressed once the initial issues are solved.

Second, when deciding on reimbursement, NHS should balance the cost of therapy against the cost of palliative, often expensive treatments over a long time. This can take from a few years in case of early fatal diseases, such as early-onset neurodegenerative diseases and some forms of epidermolysis bullosa (EB), up to decades for diseases such as hemophilia, muscular dystrophies, or several genodermatoses.

Third, ATMPs require rigorous and independent controls regarding safety and efficacy as a requisite for marketing approval.

Finally, profit is the reason for companies and it would be disingenuous to expect them to prioritize patients over profit as this would risk economic unsustainability. This holds for both smaller biotech firms and large pharmaceutical companies with a broad range of products.

3. Long-term Effectiveness and Side effects

While advancements in healthcare have led to the development of novel therapies, evaluating their long-term effectiveness and potential side effects remains a challenge. Longitudinal studies, real-world evidence, and post-marketing surveillance play vital roles in assessing treatment outcomes and adverse events. To enhance our understanding, future research directions should focus on leveraging big data analytics, incorporating patient-reported outcomes, and employing advanced monitoring technologies for continuous assessment of treatment effectiveness and safety.

Challenges in Studying Long-Term Effectiveness:

1. Lengthy Follow-Up Periods: Long-term studies require extended follow-up periods to capture sustained treatment outcomes. However, maintaining participant engagement and minimizing attrition over such durations can be challenging (Linden et al., 2021).
2. Data Collection and Analysis: Collecting accurate and reliable long-term data is a complex task.

Researchers must employ robust methodologies, address missing data issues, and account for evolving technology and treatment guidelines during the study period (Chang et al., 2020).

3. Changing Healthcare Landscape: The introduction of new treatments and evolving healthcare practices can significantly impact long-term treatment outcomes. Researchers must consider these changes and adjust their study designs and analysis accordingly (Nallamothu et al., 2019).
4. Ethical Considerations: Long-term studies must adhere to stringent ethical guidelines, ensuring participant safety, informed consent, and appropriate monitoring of adverse events. Balancing potential risks and benefits for study participants is of utmost importance (Kass et al., 2017).

Challenges in Long-Term Side Effects:

1. Rare and Delayed Adverse Events: Certain side effects may occur rarely or have a delayed onset, making their detection challenging. Large sample sizes, advanced statistical methods, and innovative study designs are necessary to capture these events (Friedman et al., 2019).
2. Cumulative Effects and Interactions: Some side effects may be cumulative or interact with other factors, such as concomitant medications or lifestyle choices. Long-term studies should employ detailed exposure and outcome assessments to unravel these complexities (Rassen et al., 2021).
3. Selection Bias and Generalizability: Participant recruitment and retention pose challenges in long-term studies, potentially introducing selection bias and limiting generalizability. Ensuring diverse and representative study populations is essential to mitigate these biases (Harron et al., 2019).

Future directions:

1. Real-World Evidence: The utilization of real-world data, including electronic health records and registries, can enhance the efficiency and generalizability of long-term studies. These data sources provide insights into real-world treatment outcomes and side effects (Schneeweiss et al., 2019).
2. Collaboration and Data Sharing: Promoting collaboration and data sharing among researchers and institutions enables the pooling of resources and data, leading to more comprehensive and robust long-term studies. This approach improves statistical power and facilitates subgroup analyses (Zarin et al., 2016).
3. Advanced Analytics and Artificial Intelligence: Integrating advanced analytics and artificial intelligence techniques, such as machine learning, can assist in analyzing large datasets, identifying patterns, and predicting potential long-term risks and side effects (Weng et al., 2017).

4. Emerging Trends and Future research directions

In the rapidly evolving landscape of scientific research, emerging trends and future research directions play a vital role in shaping the trajectory of various fields. This review article aims to highlight some of the current emerging trends across disciplines and discuss potential research directions that hold promise for future investigations.

1. Artificial Intelligence and Machine Learning:

Artificial intelligence (AI) and machine learning (ML) have witnessed significant advancements in recent years, revolutionizing various industries. In research, AI and ML are being employed to analyze complex data, identify patterns, and make predictions. Future research could focus on refining AI and ML algorithms, exploring their applications in diverse fields, and addressing ethical considerations related to their use (Esteva et al., 2019).

2. Precision Medicine and Personalized Therapies:

Precision medicine seeks to provide targeted treatments tailored to individual patient's genetic makeup, lifestyle, and environmental factors. The integration of genomics, proteomics, and other omics technologies has paved the way for personalized therapies. Future research directions may involve identifying biomarkers for early disease detection, developing innovative treatment approaches, and exploring the impact of personalized medicine on healthcare outcomes (Collins and Varmus, 2015).

3. Big Data and Data science:

The advent of big data has opened new avenues for research across disciplines. With the exponential growth of data generation and availability, data science techniques are crucial for extracting meaningful insights. Future research can focus on developing robust data analytics methods, ensuring data privacy and security, and utilizing big data to address pressing societal challenges, such as healthcare disparities and climate change (Kitchin, 2014).

4. Neuroscience and Brain Research:

Advances in neuroscience have deepened our understanding of the brain and its intricate functions. Future research may delve into decoding the mechanisms underlying neurological disorders, developing innovative treatments for brain-related conditions, exploring brain-computer interfaces, and investigating the relationship between the brain and cognitive processes, emotions, and behavior (Fries et al., 2020).

CONCLUSION

A. Recap of the importance of clinical trials in advancing cancer treatment

1. The treatment of cancer is complicated due to its diverse molecular and genetic characteristics. Clinical trials provide a platform for testing novel therapeutic approaches, enabling evidence-based advancements in cancer treatment.

2. Clinical Trial Design and Phases:
Clinical trials are accurately designed research studies that follow different phases. Phase I trials focus on safety and dosage, Phase II trials assess efficacy, and Phase III trials compare current standards to novel treatments. Each phase contributes essential information to shaping clinical practice and future research.

3. Enhancing therapeutic strategies:
Clinical trials are involved in developing innovative therapeutic strategies. Immune checkpoint inhibitors have revolutionized cancer treatment, with studies showing remarkable responses to various malignancies.

4. Personalized medicine:
Clinical trials fuel personalized medicine. Biomarker-driven trials have identified specific genetic alterations or molecular signatures that predict targeted therapies' responses. The successful enactment of targeted agents such as Imatinib in chronic myeloid leukemia and EGFR inhibitors in lung cancer exemplifies the impact of personalized medicine on the outcome of patients.

5. Pediatric oncology:
Clinical trials are crucial for advancing cancer care in children. Due to the abnormalities of pediatric cancers, collaborative trials have been crucial to evaluating novel therapies. Studies like the Children's Oncology Group trials have significantly improved survival rates for pediatric malignancies and childhood leukemia.

6. Overcoming treatment resistance:
Clinical trials also discuss treatment resistance mechanisms. Studies investigating novel combinations, immunotherapeutic approaches, and adaptive therapies aim to overcome resistance and prolong patient survival. In terms of PARP inhibitors for BRCA-mutated ovarian cancer and tyrosine kinase inhibitors for resistant EGFR-mutated lung cancer, two examples are worth noting.

7. Adverse event monitoring:
Clinical trials strictly monitor adverse events to assure patient safety. Early identification of treatment-related toxicities allows appropriate management and minimizes potential harm. Notably, clinical trials have played a crucial role in mitigating and identifying immune-related adverse events associated with immunotherapy.

8. Regulatory approvals:
Clinical trials generate essential data for the regulatory approval of new therapies. Stringent evaluation of safety and efficacy in these trials allows regulatory agencies to make more informed decisions regarding drug approvals, thereby benefiting patients and healthcare professionals.

B. Potential impact of novel therapies on patient outcomes
Novel therapies refer to treatments developed specifically to destroy cancer cells while preventing damage to healthy cells. These therapies target specific molecular pathways or use the patient's immune system to fight the disease.
Examples of novel therapies include Targeted therapies, Immunotherapies, and Gene therapies.

1. Targeted therapies:
1.1 Molecularly targeted therapies:
Molecularly targeted therapies bind to specific molecules and pathways within the body to inhibit cancer cell growth.
Examples of molecularly targeted therapies include tyrosine kinase inhibitors (TKIs - Imatinib in chronic myeloid leukemia) and monoclonal antibodies.
These therapies are developed to be more specific and have fewer side effects than conventional treatments, such as chemotherapy. The emergence of small molecule inhibitors targeting specific driver mutations (e.g., EGFR inhibitors in non-small cell lung cancer).

1.2 Antibody-Drug Conjugates (ADCs):
Antibody-drug conjugates (ADCs) are a type of targeted therapy that uses antibodies to identify and deliver toxic drugs to cancer cells. ADCs are composed of an antibody that binds to a specific target on cancer cells, and a drug payload that is released when the antibody binds to the target. This targeted approach enables the delivery of higher drug concentrations to cancer cells while avoiding healthy cells. This results in fewer side effects and improved efficacy.
The clinical success of ADCs, including brentuximab vedotin and ado-trastuzumab emtansine, in hematologic and solid malignancies.

2. Immunotherapies:
2.1 Checkpoint inhibitors: Checkpoint inhibitors represent an emerging class of immunotherapies, which harness the body's immune system to fight cancer.

The role of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 and anti-CTLA-4 antibodies) reinvigorate the immune response against cancer. The phenomenal clinical outcomes followed lung cancer, melanoma, and other malignancies.

2.2 Chimeric antigen receptor T-cell therapy:
This revolutionary therapy known as Chimeric Antigen Receptor T-cell therapy (CAR-T) has brought about potentially life-saving breakthroughs in treating not only lung cancer and melanoma but other malignancies as well.

The development of CAR T-cell therapy and its application in hematological malignancies, such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma are irreplaceable. The challenges and ongoing research to widen CAR T-cell therapy use in solid tumors.

3. Gene therapies:

3.1 Gene editing techniques

Using gene editing techniques, it is now possible to make permanent changes to an individual's genetic makeup, potentially offering treatments for a wide range of genetic diseases.

Gene editing tools, including CRISPR-Cas9, target cancer-associated genes and modify the disease-causing mutations.

The potential of gene editing for accurate medicine and overcoming treatment resistance.

3.2 Oncolytic viruses:

Oncolytic viruses selectively infect and kill tumor cells, while activating an immune response.

The clinical improvement of oncolytic viruses, such as talimogene laherparepvec, in some solid tumors and melanoma.

C. **Encouragement of continued research and participation in clinical trials**

Clinical trials play an important role in the advancement of medical knowledge, in the development of novel treatments, and in the evaluation of the effectiveness of treatment. Despite their importance, research participants pose significant challenges to researchers in recruiting and retaining them.

1. Fostering a research culture:

In clinical trials participation, and initiating a research culture within healthcare organizations and communities is crucial. For advancing medical science, collaboration among healthcare providers, researchers, and patients can enable shared responsibilities and can facilitate clinical research. Formulating clinical research by assigning research networks, and acknowledging participants' assistance and training possibilities can help us achieve this objective.

2. Enhancing participant engagement:

Enhancing recruitment and retention rates through active engagement of participants throughout the clinical trial process. Ensuring effective communication techniques with clinical trial participants, involving participants in clinical trial design, delivering periodic updates regarding the trial, and providing apparent information about study objectives and procedures are crucial. Including patient advocacy groups and patient-reported outcomes additionally can improve participant engagement.

3. Addressing barriers to participation:

In clinical trials, it is essential to understand and address barriers that hinder individuals from participating in clinical trials. These barriers may include language and cultural barriers, logistical challenges, lack of awareness, safety concerns, and economic considerations. By educating participants, improving convenience and accessibility, providing financial support, and addressing diversity and inclusion, we can overcome these barriers.

4. Leveraging Technology and Social media:

To enhance clinical trial participation, the use of technology and social media platforms will be necessary. Online platforms facilitate the recruitment of participants, provide virtual study visits, and provide easy access to information. In addition to collecting real-time data, mobile applications, and wearable devices can enhance participants' experience and improve their compliance. In circulating awareness, engaging participants, and enabling virtual communities social media plays a crucial role. Ultimately, these strategies can increase efficiency, improve patient outcomes, and decrease clinical trial costs.

5. Promoting Patient-Centered approaches:

To encourage ongoing participation in clinical trials adopting a patient-centered approach is critical. This approach refers to the amendment of study protocols to meet patients' preferences and requirements. A participant-friendly environment will be essential and will engage patients in decision-making processes. By creating a sense of privilege and promoting the continued engagement of participants in clinical trials. This is done by emphasizing the importance of providing their assistants with feedback on study outcomes.

6. Regulatory and Policy Considerations:

Clinical trial participation should support regulatory frameworks and policies. Encouraging and promoting informed consent and broader access to trial results which includes vital aspects. Assuring data security, privacy and paying for participants' time and expenses is a prior consideration. To implement effective policies, regulatory bodies, research organizations, and industry stakeholders should work cooperatively.

REFERENCE

1. https://cancer.umn.edu/news/what-are-cancer-clinical-trials
2. https://sprintmedical.in/blog/novel-therapies-for-cancer
3. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/immunotherapy-and-vaccines/what-
4. Ankur Rohilla*, Ravi Kumar Singh, et.,al phases of clinical trials: a review, *international journal of pharmaceutical, chemical and biological sciences*, 2013; 3(3): 700-703.
5. https://www.ppd.com/participate-in-clinical-trial/investigators/informed-consent/
6. Gupta UC. Informed consent in clinical research: Revisiting few concepts and areas. *National Library of Medicine*, 2013; 4(1): 26-32.
7. Chaudhari N, Ravi R, Gogtay NJ, Thatte UM. Recruitment and retention of the participants in clinical trials: Challenges and solutions. *National Library of Medicine*, 2020; 11(2): 64-69.

8. https://toolbox.eupati.eu/resources/enrolling-in-clinical-trials/
9. https://school.wakehealth.edu/education-and-training/graduate-programs/clinical-research-management-
10. https://clinicalcenter.nih.gov/recruit/ethics.html
11. https://www.cloudbyz.com/resources/patient-recruitment/how-to-ensure-patient-safety-during-a-clinical-trial
12. Dr J M Kendall., Designing a research project: randomised controlled trials and their principles, *British medical journal.*
13. Megan Othus, Mei-Jie Zhang etal, Clinical trials: design, endpoints and interpretation of outcomes. *Bone Marrow Transplant*, 2022; 57: 338–342
14. https://handbook.unimelb.edu.au/2020/subjects/clrs90010
15. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
16. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139602/
17. Shiravand Y, Khodadadi F etal, A. Immune Checkpoint Inhibitors in Cancer Therapy. *National Library of Medicine*, 2022; 24, 29(5): 3044-3060.
18. https://www.cancerresearchuk.org/about19
19. cancer/treatment/immunotherapy/types/checkpoint-inhibitors
20. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
21. https://www.lls.org/treatment/types-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy
22. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/what-targeted-therapy
23. https://www.ncbi.nlm.nih.gov/books/NBK563322/
24. Robert J. Thomson; Majid Moshirfar; Yasmyne Ronquillo., Tyrosine Kinase Inhibitors National library of medicine, 2023; 1.
25. https://www.lls.org/leukemia/chronic-myeloid-leukemia/treatment/tyrosine-kinase-inhibitor-tki-therapy
26. https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs/types/monoclonal-antibodies
27. Adams, J. Proteasome Inhibitors in Cancer Therapy. Cancer Drug Discovery and Development, 2004. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-767-3_41
28. https://www.thelancet.com/pdfs/journals/lancet/PIIS0140673697900131.pdf
29. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1570487
30. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future, *National Library of Medicine*, 2006; 4(3): 218-27.
31. Zhang, H., Qin, C., An, C. *et al.* Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer. *Mol Cancer, 2021;* 20: 126.
32. https://www.cancerresearch.org/treatment-types/oncolytic-virus-therapy
33. https://onlinelibrary.wiley.com/doi/full/10.1111
34. Wang, J., Xu, B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. *Sig Transduct Target Ther*, 2019; 4: 34.
35. Kadam RA, Borde SU, Madas SA, Salvi SS, Limaye SS. Challenges in recruitment and retention of clinical trial subjects. Perspect Clin Res, 2016; 7(3): 137-43. doi 10.4103/2229-3485.184820. PMID: 27453831; PMCID: PMC4936073.
36. Danzon, P. M. Toward a broader concept of value: Identifying and defining elements for an expanded cost-effectiveness analysis. Value in Health, 2013; 16(4): S12-S16.
37. Bach, P. B. Limits on Medicare's ability to control rising spending on cancer drugs. New England Journal of Medicine, 2017; 376(6): 506-513.
38. Sherman, R. E., Anderson, S. A., Dal Pan, G. J., Gray, G. W., Gross, T., Hunter, N. L., ... & Temple, R. Real-world evidence-What is it and what can it tell us? New England Journal of Medicine, 2016; 375(23): 2293-2297.
39. Gliklich, R. E., & Dreyer, N. A. (Eds.). Registries for evaluating patient outcomes: A user's guide. Agency for Healthcare Research and Quality, 2014.
40. Chang, H., et al. Methodological considerations for the design and analysis of long-term observational studies. Journal of Thoracic Disease, 2020; 12(1): S21-S32.
41. Friedman, L. M., et al. Fundamentals of Clinical Trials. Springer, 2019.
42. Harron, K., et al. Challenges in researching electronic health records. BMJ, 2019; 368: l6969.
43. Kass, N. E., et al. The use of central institutional review boards for multicenter clinical trials in the United States: A review of the literature. Clinical Trials, 2017; 14(4): 342-348.
44. Linden, A., et al. Challenges and opportunities in long-term follow-up studies. Journal of Evaluation in Clinical Practice, 2021; 27(1): 1-7.
45. Nallamothu, B. K., et al.Addressing the twin challenges of cardiovascular device innovation and postmarket surveillance. JAMA, 2019; 321(11): 1049-1050.
46. Rassen, J. A., et al. Designing and implementing rigorous studies of the safety of therapeutics in pregnancy: Challenges, progress, and future directions. Pharmacoepidemiology and Drug Safety, 2021; 30(3): 259-265.
47. Schneeweiss, S., et al. Real-world evidence studies in the era of data privacy protection: A framework for assessing data source and quality in relation to study types and research objectives. Pharmacoepidemiology and Drug Safety, 2019; 28(5): 573-583.

48. Weng, S. F., et al. Can machine learning improve cardiovascular risk prediction using routine clinical data? PLoS ONE, 2017.
49. Zarin, D. A., et al. Trial Reporting in ClinicalTrials.gov—The Final Rule. New England Journal of Medicine, 2016; 375(20): 1998-2004.
50. Collins, F. S., & Varmus, H. A New Initiative on Precision Medicine. New England Journal of Medicine, 2015; 372(9): 793-795.
51. Esteva, A., et al. A guide to deep learning in healthcare. Nature Medicine, 2019; 25(1): 24-29.
52. Fries, P., et al. Neuronal gamma oscillations: Their role in human cognition and pathology. Trends in Neurosciences, 2020; 43(1): 24-35.
53. Kitchin, R. Big data, new epistemologies, and paradigm shifts. Big Data & Society, 2014; 1(1), 2053951714528481.
54. Smith A, et al. Advancements in clinical trial design for precision medicine in oncology. Oncologist, 2021; 26(3): e467-e476.
55. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001; 344(11): 783-792.
56. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012; 366(26): 2443-2454.
57. O'Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 2003; 348(11): 994-1004.
58. Mok TS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009; 361(10): 947-957.
59. Pui CH, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol, 2015; 33(27): 2938-2948.
60. Ledermann JA, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer. N Engl J Med, 2012; 366(15): 1382-1392.
61. Yu HA, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res, 2013; 19(8): 2240-2247.
62. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2018; 68(6): 394-424.
63. Hanahan, D., & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell, 2011; 144(5): 646-674.
64. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 2001; 344(14): 1031-1037.
65. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 2009; 361(10): 947-957.
66. Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New England Journal of Medicine, 2010; 363(19): 1812-1821.
67. Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized, open-label, phase 3 trial. The Lancet Oncology, 2017; 15(7): 689-699.
68. Brahmer, J. R. et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. New England Journal of Medicine, 2015; 373(2): 123-135.
69. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 2010; 363(8): 711-723.
70. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 2014; 371(16): 1507-1517.
71. Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 2017; 377(26): 2531-2544.
72. Doudna, J. A., & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014; 346(6213): 1258096.
73. Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science, 2020; 367(6481): eaba7365.
74. Andtbacka, R. H. et al. Talimogene laherparepvec improves the durable response rate in patients with advanced melanoma. *Journal of Clinical Oncology*, 2015; 33(25): 2780-2788.
75. Kaufman, H. L. et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. *Journal of Clinical Investigation*, 2010; 115(7): 1903-1912.